HIV/AIDS

Featured Article
Costs of HIV PrEP Could Curb Expansion, Researchers Warn
Payments for HIV PrEP medication in the United States totaled more than $2.08 billion in 2018, according to a Centers for Disease Control and Prevention study recently published in Annals of Internal Medicine.
HIV/AIDS Costliest Chronic Condition Cluster in US Analysis
“The relatively recent phenomenon of co-existence and clustering of chronic communicable conditions, such as HIV, with highly-prevalent noncommunicable diseases, represents a serious threat for a…
Addressing Barriers to Preventive HIV Care for At-Risk Patient Populations
Ed Pezalla, MD, CEO, Enlightenment Bioconsult LLC, speaks about the barriers to preventive HIV care, pinpoints how payers can reach at-risk populations, and reviews the US Preventive Services Task…

Newsfeed

Costs of HIV PrEP Could Curb Expansion, Researchers Warn
HIV/AIDS Costliest Chronic Condition Cluster in US Analysis
Addressing Barriers to Preventive HIV Care for At-Risk Patient Populations
HHS Improves HIV/AIDS Care, Support, Access With More Than $2 Billion in Grants
Examining a New Class of Antiretroviral Therapy for Patients With Multidrug-Resistant HIV-1 Infection
HIV PrEP Medication Costs US More Than $2 Billion Annually
Comparing Access, Usage of PrEP in Newly Diagnosed vs Patients Living With HIV
Understanding Cost Burden of HIV, PrEP Under Medicare Part D
View More

Insights

Examining a New Class of Antiretroviral Therapy for Patients With Multidrug-Resistant HIV-1 Infection
Max Lataillade, DO, head of global research strategy, ViiV Healthcare, discusses the findings of the BRIGHTE study that demonstrated a significant decrease in HIV-1 RNA levels among patients treated with fostemsavir, a first-in-class investigational…
Addressing Treatment and Prevention of HIV
While great strides have been made in treating people with HIV over the past few decades, the US Preventive Task Force is strongly recommending PrEP for anyone at risk to help prevent the spread of the disease with which approximately 1.1 million…
Generics for HIV: Complex Barriers Impede the Uptake
A number of barriers are keeping patients from gaining access to cheaper, generic versions of HIV treatment medications.
View More

Interactive Features

Addressing Barriers to Preventive HIV Care for At-Risk Patient Populations
Ed Pezalla, MD, CEO, Enlightenment Bioconsult LLC, speaks about the barriers to preventive HIV care, pinpoints how payers can reach at-risk populations, and reviews the US Preventive Services Task Force’s measures requiring health plans to provide…
View More
Back to Top